Trial Profile

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpha-tocopheroloxyacetic acid-Veana-Therapeutics (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Veana Therapeutics

Most Recent Events

10 Jul 2024 Planned End Date changed from 1 Feb 2025 to 1 Feb 2030.
10 Jul 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2028.
10 Jul 2024 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com